2,4-thiazolidinedione

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
2,4-thiazolidinedione
DrugBank Accession Number
DB11898
Background

Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 117.12
Monoisotopic: 116.988449515
Chemical Formula
C3H3NO2S
Synonyms
  • Thiazolidinedione
External IDs
  • NSC-6745

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with 2,4-thiazolidinedione.
AcebutololThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with 2,4-thiazolidinedione.
Acetyl sulfisoxazoleThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with 2,4-thiazolidinedione.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with 2,4-thiazolidinedione.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with 2,4-thiazolidinedione.
AlogliptinThe risk or severity of hypoglycemia can be increased when Alogliptin is combined with 2,4-thiazolidinedione.
AmcinonideThe risk or severity of hyperglycemia can be increased when Amcinonide is combined with 2,4-thiazolidinedione.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiazolidinediones. These are heterocyclic compounds containing a thiazolidine ring which bears two ketone groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Thiazolidines
Direct Parent
Thiazolidinediones
Alternative Parents
Dicarboximides / Thiocarbamic acid derivatives / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic heteromonocyclic compound / Azacycle / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative / Dicarboximide / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
thiazolidenedione (CHEBI:50992)
Affected organisms
Not Available

Chemical Identifiers

UNII
AA68LXK93C
CAS number
2295-31-0
InChI Key
ZOBPZXTWZATXDG-UHFFFAOYSA-N
InChI
InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1H2,(H,4,5,6)
IUPAC Name
1,3-thiazolidine-2,4-dione
SMILES
O=C1CSC(=O)N1

References

General References
Not Available
PubChem Compound
5437
PubChem Substance
347828231
ChemSpider
5242
ChEBI
50992
ChEMBL
CHEMBL85398
ZINC
ZINC000008554292

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentNonalcoholic Fatty Liver / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus2
3CompletedTreatmentType 2 Diabetes Mellitus4
3RecruitingTreatmentDiabetes Mellitus / Endocrine System Diseases / Glucose Metabolism Disorders / Hypoglycemic Agents / Metabolic Diseases / Type 2 Diabetes Mellitus1
1CompletedNot AvailableBMI >30 kg/m2 / Insulin Resistance / Syndrome, Metabolic1
1CompletedTreatmentType 1 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Insulin Resistance1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingBasic ScienceUric Acid Kidney Stone Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility77.9 mg/mLALOGPS
logP-0.88ALOGPS
logP-0.28ChemAxon
logS-0.18ALOGPS
pKa (Strongest Acidic)7.36ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.17 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity25.54 m3·mol-1ChemAxon
Polarizability9.66 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0avl-9100000000-a54a2ac7c249a408e0b2
GC-MS Spectrum - EI-BGC-MSsplash10-0002-9200000000-f5f3bbe3b05d2cd8d44b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 20:58 / Updated on June 12, 2020 16:53